Serum platelet-activating factor acetylhydrolase activity: A novel potential inflammatory marker in type 1 diabetes

Prostaglandins and Other Lipid Mediators

Volumn 87, Issue 1-4, 2008, Pages 42-46

  Gomes, Marilia de Brito ^a   Cobas, Roberta Arnold ^a   Nunes, Edson ^b   Nery, Michele ^a   Castro Faria Neto, Hugo Caire ^b   Tibiriçá, Eduardo ^a,b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Chronic complications; Diabetes type 1; Inflammatory markers; Platelet activating factor acetylhydrolase activity

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOCYTE ACTIVATING FACTOR; URIC ACID;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; SMOKING HABIT; URIC ACID BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFLAMMATION; MALE;

EID: 55549105747     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2008.07.001     Document Type: Article

References (48)

1. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
2. Laing S.P., Swerdlow A.J., Slater S.D., et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46 (2003) 760-765
3. Orchard T.J., Forrest K.Y., Kuller L.H., and Becker D.J. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 24 (2001) 1053-1059
4. Kuyvenhoven J.P., and Meinders A.E. Oxidative stress and diabetes mellitus: Pathogenesis of long-term complications. Eur J Intern Med 10 (1999) 9-19
5. Orchard T.J., Olson J.C., Erbey J.R., et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 26 (2003) 1374-1379
6. Colhoun H.M., Schalkwijk C., Rubens M.B., and Stehouwer C.D. C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care 25 (2002) 1813-1817
7. Ladeia A.M., Ladeia-Frota C., Pinho L., Stefanelli E., and Adan L. Endothelial dysfunction is correlated with microalbuminuria in children with short-duration type 1 diabetes. Diabetes Care 28 (2005) 2048-2050
8. Nogueira V.G., and Gomes M.B. Acute-phase proteins and microalbuminuria among patients with type 2 diabetes. Diabetes Res Clin Pract 66 (2004) 31-39
9. Stehouwer C.D., Gall M.A., Twisk J.W., Knudsen E., Emeis J.J., and Parving H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51 (2002) 1157-1165
10. Jager A., van Hinsbergh V.W., Kostense P.J., et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 22 (2002) 593-598
11. Gomes M.B., Piccirillo L.J., Nogueira V.G., and Matos H.J. Acute-phase proteins among patients with type 1 diabetes. Diabetes Metab 29 (2003) 405-411
12. Schalkwijk C.G., Poland D.C., van Dijk W., et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42 (1999) 351-357
13. Ladeia A.M., Stefanelli E., Ladeia-Frota C., Moreira A., Hiltner A., and Adan L. Association between elevated serum C-reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care 29 (2006) 424-426
14. Derewenda Z.S., and Ho Y.S. PAF-acetylhydrolases. Biochim Biophys Acta 1441 (1999) 229-236
15. Stafforini D.M., Prescott S.M., and McIntyre T.M. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem 262 (1987) 4223-4230
16. Karasawa K., Harada A., Satoh N., Inoue K., and Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 42 (2003) 93-114
17. Tjoelker L.W., and Stafforini D.M. Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta 1488 (2000) 102-123
18. Caslake M.J., Packard C.J., Suckling K.E., Holmes S.D., Chamberlain P., and Macphee C.H. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
19. Cavallo-Perin P., Lupia E., Gruden G., et al. Increased blood levels of platelet-activating factor in insulin-dependent diabetic patients with microalbuminuria. Nephrol Dial Transplant 15 (2000) 994-999
20. Serban M., Tanaseanu C., Kosaka T., et al. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus. J Cell Mol Med 6 (2002) 643-647
21. Kujiraoka T., Iwasaki T., Ishihara M., et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 44 (2003) 2006-2014
22. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
23. Carlquist J.F., Muhlestein J.B., and Anderson J.L. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 7 (2007) 511-517
24. Gazi I., Lourida E.S., Filippatos T., Tsimihodimos V., Elisaf M., and Tselepis A.D. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 51 (2005) 2264-2273
25. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109 (2004) 837-842
26. Brilakis E.S., McConnell J.P., Lennon R.J., Elesber A.A., Meyer J.G., and Berger P.B. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26 (2005) 137-144
27. Koenig W., Twardella D., Brenner H., and Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26 (2006) 1586-1593
28. Barnes P.J., Chung K.F., and Page C.P. Inflammatory mediators of asthma: an update. Pharmacol Rev 50 (1998) 515-596
29. Gomes R.N., Bozza F.A., Amancio R.T., et al. Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock 26 (2006) 41-49
30. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods WHO monograph series 1982;56:162.
31. Blackburn H., Keys A., Simonson E., Rautaharju P., and Punsar S. The electrocardiogram in population studies. A classification system. Circulation 21 (1960) 1160-1175
32. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
33. ADA. Nephropathy in diabetes. Diabetes Care 27 (2004) S79-S83
34. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
35. Aarsman A.J., Neys F.W., and Van den Bosch H. Catabolism of platelet-activating factor and its acyl analog. Differentiation of the activities of lysophospholipase and platelet-activating-factor acetylhydrolase. Eur J Biochem 200 (1991) 187-193
36. Cederholm A., Svenungsson E., Stengel D., et al. Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 50 (2004) 2869-2876
37. Papavasiliou E.C., Gouva C., Siamopoulos K.C., and Tselepis A.D. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transplant 21 (2006) 1270-1277
38. Milionis H.J., Tambaki A.P., Kanioglou C.N., Elisaf M.S., Tselepis A.D., and Tsatsoulis A. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid 15 (2005) 455-460
39. Rizos E., Tambaki A.P., Gazi I., Tselepis A.D., and Elisaf M. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 203-209
40. Marra G., Cotroneo P., Pitocco D., et al. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care 25 (2002) 370-375
41. Stafforini D.M., McIntyre T.M., Carter M.E., and Prescott S.M. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 262 (1987) 4215-4222
42. Marathe G.K., Davies S.S., Harrison K.A., et al. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem 274 (1999) 28395-28404
43. Silva A.R., de Assis E.F., Caiado L.F., et al. Monocyte chemoattractant protein-1 and 5-lipoxygenase products recruit leukocytes in response to platelet-activating factor-like lipids in oxidized low-density lipoprotein. J Immunol 168 (2002) 4112-4120
44. Taketo M.M., and Sonoshita M. Phospholipase A2 and apoptosis. Biochim Biophys Acta 1585 (2002) 72-76
45. Winkler K., Abletshauser C., Friedrich I., Hoffmann M.M., Wieland H., and Marz W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 1153-1159
46. Forte T.M., Subbanagounder G., Berliner J.A., et al. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res 43 (2002) 477-485
47. Singh U., Zhong S., Xiong M., Li T.B., Sniderman A., and Teng B.B. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin Sci (Lond) 106 (2004) 421-432
48. Renard C.B., Kramer F., Johansson F., et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 114 (2004) 659-668